Overview
- A Neuron paper published Monday reports that systemic antibody blockade of the chemokine receptor CXCR3 cut brain‑infiltrating T cells by about half, preserved roughly 40% more tissue in hippocampal memory regions, and improved memory in mice without reducing tau tangles.
- Prior work from the same lab showed the harmful T cells are primed outside the brain by classical dendritic cells in cervical lymph nodes, establishing a peripheral origin for the damaging immune response.
- The study identifies a CXCL10–CXCR3 chemotactic pathway that guides activated T cells into the brain, and genetic loss or antibody blockade of CXCR3 prevents that infiltration.
- The CXCR3 antibody accumulated at brain borders and did not enter parenchyma, which suggests therapies can act on accessible peripheral or border tissues rather than crossing the blood–brain barrier.
- Researchers are now testing midlife timing, seeking the molecular signals that carry brain material to lymph nodes, and exploring whether existing T‑cell therapies could be repurposed for human tauopathies, but translation to people remains unproven.